+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Insulin Aspart"

Type 1 Diabetes Market Report 2025 - Product Thumbnail Image

Type 1 Diabetes Market Report 2025

  • Report
  • March 2025
  • 200 Pages
  • Global
From
Insulin Drugs Market Report 2025 - Product Thumbnail Image

Insulin Drugs Market Report 2025

  • Report
  • March 2025
  • 175 Pages
  • Global
From
Insulin Biosimilars Market Report 2025 - Product Thumbnail Image

Insulin Biosimilars Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
From
Type 1 Diabetes - Pipeline Insight, 2024 - Product Thumbnail Image

Type 1 Diabetes - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 220 Pages
  • Global
From
From
Type 1 Diabetes: Seven-Market Drug Forecast and Market Analysis - Product Thumbnail Image

Type 1 Diabetes: Seven-Market Drug Forecast and Market Analysis

  • Report
  • December 2024
  • 144 Pages
  • Global
From
US Biosimilar Insulin Market Opportunity & Clinical Trials Insight 2026 - Product Thumbnail Image

US Biosimilar Insulin Market Opportunity & Clinical Trials Insight 2026

  • Report
  • August 2021
  • 50 Pages
  • United States
From
From
From
From
From
From
From
From
From
Loading Indicator

Insulin Aspart is a fast-acting insulin analog used to treat diabetes mellitus, a metabolic disorder. It is used to control high blood sugar levels in adults and children with type 1 diabetes and adults with type 2 diabetes. Insulin Aspart is a recombinant human insulin analog that is produced by recombinant DNA technology. It is a short-acting insulin that is used to control post-meal blood sugar levels. It is usually taken before meals and can be used in combination with other diabetes medications. Insulin Aspart is part of the Endocrine and Metabolic Disorders Drugs market, which includes medications used to treat endocrine and metabolic disorders such as diabetes, thyroid disorders, and obesity. These drugs are used to control blood sugar levels, regulate hormones, and reduce the risk of complications associated with metabolic disorders. Companies in the Insulin Aspart market include Novo Nordisk, Eli Lilly, Sanofi, and Merck. Show Less Read more